血清固定梅毒孕妇的血清学应答与妊娠结局:前瞻性巢式病例对照研究再治疗疗效
前瞻性巢式病例对照研究纳入584例血清固定梅毒孕妇,537例(92.0%)妊娠结局正常,与无梅毒孕妇的93.6%相当。在充分产前保健和持续血清学监测下,无需对血清固定且非梅毒螺旋体抗体滴度稳定的孕妇进行再治疗。
要点
- 584例血清固定梅毒孕妇中92.0%妊娠结局正常,与无梅毒孕妇93.6%相当。
- 462例随访新生儿中未发现先天梅毒病例。
核心结论
- 在充分产前保健和持续监测血清学及症状变化的情况下,无需对妊娠期非梅毒螺旋体抗体滴度稳定的血清固定梅毒孕妇进行再治疗。
研究设计与样本
- 前瞻性巢式病例对照研究,分析584例血清固定梅毒孕妇的血清学应答和妊娠结局,聚焦再治疗效果。
主要发现
- 584例中537例(92.0%)妊娠结局正常,与无梅毒孕妇的93.6%相当。
- 47例(8.0%)发生不良妊娠结局,包括8例(1.4%)自然流产、2例(0.3%)宫内死胎和37例(6.3%)早产或低出生体重。
- 462例随访新生儿中未发现先天梅毒病例。
临床怎么用
- 对血清固定且非梅毒螺旋体抗体滴度稳定的梅毒孕妇,在充分产前保健和持续血清学及症状监测下,无需再治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are inconsistencies in guidelines concerning the necessity for anti-syphilis retreatment during pregnancy for women who tested seropositive despite having received treatment before pregnancy. While global guidelines indicate that no further treatment is necessary, Chinese guidelines advocate for an additional treatment course. METHODS: A prospective nested case-control study was conducted to analyze serological responses and pregnancy outcomes in women with serofast syphilis, focusing on the effects of retreatment. RESULTS: Of 584 women with serofast syphilis, 537 (92.0%) experienced normal pregnancy outcomes, comparable to the 93.6% in women without syphilis. However, 47 (8.0%) faced adverse pregnancy outcomes (APOs), which included 8 (1.4%) spontaneous abortions, 2 (0.3%) intrauterine fetal deaths, and 37 (6.3%) instances of preterm birth or low birth weight. The rate of APOs showed no significant difference between those treated with benzathine penicillin G and those who were not (adjusted odds ratio [aOR], 0.59 [95% confidence interval {CI}, .31-1.14]; P = .118). Among 462 newborns with follow-up, no congenital syphilis cases were identified. Serological responses were evaluated in 568 women, revealing that 74 (13.0%) experienced seroreversion of nontreponemal antibodies, 52 (9.2%) had a ≥4-fold decrease in titers, 6 (1.0%) had a ≥4-fold increase in titers, and 436 (74.7%) maintained stable titers. No significant difference in seroreversion rate was found between the retreated and non-retreated groups (aOR, 1.43 [95% CI, .76-2.71]; P = .271). CONCLUSIONS: With adequate prenatal care and continuous monitoring of serological and symptomatic changes, it is unnecessary to retreat serofast women exhibiting stable nontreponemal antibody titers during pregnancy.
引用
- Yan RL, Xu Y, Tong J, et al. Serological Responses and Pregnancy Outcomes in Women With Serofast Syphilis: Efficacy of Retreatment in a Prospective Nested Case-Control Study. J Infect Dis. 2025. PMID: 40233182. doi:10.1093/infdis/jiaf193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。